It was reported yesterday that Ardelyx, Inc (NASDAQ: ARDX), a company focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines, has named Jan M Lundberg, PhD as a director, effective 23 March 2018.

Lundberg has more than 22 years of experience in biopharma research. He is currently executive vice president, science and technology, and president, Lilly Research Laboratories at Eli Lilly where he has overseen submission and approval of 10 new products over the last five years.

Previously, he was global head of discovery research at AstraZeneca, focused on various drug candidate nominations, development projects and marketed-product support, and in-licensing, partnering and acquisitions. He has also served as the head of preclinical research at Astra AB and was a co-founder of Aerocrine AB.